戈利木单抗免疫原性及其在类风湿关节炎、银屑病关节炎和强直性脊柱炎患者中的临床相关性
本研究开发了高灵敏度耐药酶免疫分析(DT-EIA)并交叉验证原EIA,重新检测了戈利木单抗皮下注射治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎的三项3期试验样本。DT-EIA检测的抗药抗体(ADA)发生率较原EIA提高8倍(31.7% vs 4.1%),新检出ADA多为低滴度,高滴度(≥100)对戈利木单抗谷浓度影响更明显,但ADA对临床疗效或注射部位反应无影响。
要点
- DT-EIA较原EIA显著提高ADA检出率(31.7% vs 4.1%)。
- 新检出ADA多为低滴度,高滴度(≥100)对戈利木单抗谷浓度影响更明显。
- ADA对临床疗效或注射部位反应无影响。
核心结论
- 使用DT-EIA检测的ADA发生率高于原EIA,新检出ADA多为低滴度,对临床疗效或注射部位反应无影响,与原EIA结果一致。
研究设计与样本
- 开发高灵敏度耐药EIA(DT-EIA)并与原EIA交叉验证,重新检测戈利木单抗皮下注射治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎的三项3期试验样本。
主要发现
- DT-EIA较原EIA更敏感,可在远高于免疫原性检测样本的戈利木单抗浓度下检测ADA。
- DT-EIA检出ADA发生率为31.7%,原EIA为4.1%,提高8倍。
- DT-EIA检出的ADA阳性患者大多抗体滴度较低,高滴度者大多原EIA已检出。
- DT-EIA检测下ADA阳性患者戈利木单抗谷浓度通常低于ADA阴性患者,高滴度(≥100)时影响更明显。
- ADA对临床疗效或注射部位反应无明显影响。
关键数值与推荐
- ADA发生率:DT-EIA 31.7% vs 原EIA 4.1%。
- 高ADA滴度定义为≥100。
临床怎么用
- 临床解读戈利木单抗ADA时需注意检测方法敏感性差异,低滴度ADA可能无临床影响。
- 高滴度ADA(≥100)与戈利木单抗谷浓度降低相关,但未发现对疗效或注射部位反应的影响。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Golimumab immunogenicity was extensively studied during clinical development. As anti-drug antibody (ADA) detection with the standard bridging EIA (original-EIA) can yield false-negative results or underestimate ADA incidence and titres due to drug interference, a more sensitive assay was needed to determine clinical impact. METHODS: A highly sensitive drug-tolerant EIA (DT-EIA) was developed and cross-validated against the original-EIA. Samples from phase-3 subcutaneous golimumab rheumatological trials (GO-FORWARD-rheumatoid arthritis, GO-REVEAL-psoriatic arthritis, GO-RAISE-ankylosing spondylitis) were then retested. Associations between ADAs and golimumab pharmacokinetics, efficacy and safety were assessed. RESULTS: The DT-EIA was more sensitive than the original-EIA and capable of detecting ADAs amid golimumab concentrations far exceeding those in immunogenicity test samples. Consequently, an 8-fold increase in the incidence of ADAs was observed with the DT-EIA (31.7%) vs original-EIA (4.1%) in the studies. Most ADA-positive patients identified by the DT-EIA had lower antibody titres, while most with higher titres were previously identified as ADA-positive by the original-EIA. With the DT-EIA, ADA-positive patients generally had lower trough serum golimumab concentrations than ADA-negative patients; however, ADA impact on serum golimumab concentrations was more notable at higher ADA titres (⩾100). No impact of ADAs on clinical efficacy or injection-site reactions was evident. CONCLUSION: ADA incidence was expectedly higher using the DT-EIA vs original-EIA; newly detected ADAs were characterized mostly by low titres, with no impact on clinical efficacy or injection-site reactions, consistent with previously observed original-EIA results. Golimumab immunogenicity with the DT-EIA is consistent with existing knowledge regarding the clinical relevance of ADAs detected with the original-EIA in patients with rheumatological disorders. TRIAL REGISTRATION: NCT00264550, NCT00265096, NCT00265083.
引用
- Leu JH, Adedokun OJ, Gargano C, et al. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Rheumatology (Oxford). 2019. PMID: 30412238. doi:10.1093/rheumatology/key309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。